Onconetix, Inc. Defined Benefit Plan, Expected Future Benefit Payment, Remainder of Fiscal Year
Onconetix, Inc. (ONCO) had Defined Benefit Plan, Expected Future Benefit Payment, Remainder of Fiscal Year of $113.00 thousand as of 2025-03-31, per its 10-Q filed 2025-06-12.
Financial Statements › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Expected Future Benefit Payment
us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsRemainderOfFiscalYear · last filed 2025-06-12
- 2025-03-31: Defined Benefit Plan, Expected Future Benefit Payment, Remainder of Fiscal Year $113.00K.
| Period end | Defined Benefit Plan, Expected Future Benefit Payment, Remainder of Fiscal Year |
|---|---|
| 2025-03-31 | $113.00K 10-Q · filed 2025-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |